Fig. 3.

DC vaccination with or without PD-1 mAb blockade results in elevated [¹⁸F]-FAC probe accumulation in gliomas and directly correlates with lymphocytic infiltrate. (A–C) Representative whole-body cross-sections of PET-imaged mice injected with [¹⁸F]-FAC radioactive label for control, DCVax-treated, and DCVax + PD-1 mAb-treated mice. (D) [¹⁸F]-FAC PET probe uptake in tumor was significantly elevated in treated mice compared with untreated mice (*P < 0.05, **P < 0.01); n = 4–6/group. (E) Absolute counts of CD3⁺ tumor-infiltrating lymphocytes were significantly elevated in treated mice compared with untreated mice (**P < 0.01, ***P < 0.001); n = 4/group. (F) Correlation between the average PET probe uptake per group (D) and the average absolute infiltrating CD3+ lymphocyte count (E) per group quantified (R² = 0.89) across treatment groups.